Cellmid records highest ever quarterly sales for Evolis®

By Megan Graham. Published at Oct 11, 2016, in Biotech

Cellmid Limited (ASX:CDY) launched its Evolis® range of professional anti-aging hair care products in Australia in June this year. Today, the company reported that since launch its product range has clocked up an impressive $1,022,913 in sales for Q1 FY2017.

The company has exceeded its aim to reach a million dollars in sales, exceeding the limit comfortably by $22,000 – an excellent start to the 2017 financial year.

The Evolis® range of hair care products is sold through the company’s wholly owned subsidiary Advangen Limited, which sell a distinctive FGF5 inhibitor product for hair loss.

The reason for these strong results could be Cellmid’s new regional advertising program, as website sales grow and the company see social and digital marketing campaigns deliver returns.

Overall, sales were up by 30 per cent compared with the same period in FY2016. And that’s before the products hit the US market – which is next on the list, with commencement of US sales expected to occur in Q2 FY2017.

Cellmid is a biotechnology company which operates across life sciences and also develops and markets innovative and novel therapies, as well as diagnostic tests, for fibrotic diseases, cancer ischemic diseases of the heart and for hair loss.

The company generates millions of dollars of revenue through its hair loss business, Advangen, backed by a strong foundation of intellectual property relating to FGF5.

These products were already available in Japan before their recent launch in Australia. They’re designed not just to prevent hair loss and increase hair growth, but also maximise scalp health and hair condition.

Between FY2014, when Cellmid acquired Advangen Inc, and FY2016, sales increased by 171 per cent. 2016 was the first financial year Advangen were able to claim as profitable. Along the way the company has seen growth not just in revenue, but in profitability, with normalised income cover growing from 37 to 57 per cent in the same timeframe.

This level of growth is not guaranteed to continue and investors should seek professional financial advice if considering CDY for their portfolio.

The push for sales shows no sign of slowing, as CDY eagerly look to grow the business, and increase profits, by developing their product footprint globally.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn